Beta Bionics receives FDA clearance for Mint, a rechargeable-free patch insulin pump, and submits its 3D Intelligence dosing algorithm for FDA review.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Beta Bionics has secured U.S. Food and Drug Administration (FDA) clearance for Mint, expanding its automated insulin delivery (AID) portfolio beyond the tubed iLet system. The patch pump uses a two-piece reusable and disposable architecture, supports smartphone control on iOS and Android, and integrates with leading continuous glucose monitors (CGMs).
The company expects full U.S. commercialization to begin in the first quarter of 2027, earlier than previously planned, with manufacturing capacity targeting at least 1.5 million disposable Mint units during 2027.
Mint Uses a Reusable-Disposable Architecture
Mint separates the reusable component from the disposable insulin-delivery component. Users can change the disposable patch without re-pairing their smartphone. The system provides a 200-unit insulin reservoir, three days of wear followed by a 12-hour grace period, and an IPX8 waterproof rating for up to 5 feet of water for 60 minutes. It does not require recharging and supports firmware-over-the-air updates.
Mint is expected to work with Dexcom G7, Dexcom G7 15 Day, and Abbott’s FreeStyle Libre 3 Plus CGMs. Beta Bionics plans to distribute the system exclusively through the pharmacy channel, with approximately 40% of insured U.S. lives expected to have pharmacy-benefit access initially and at least 50% within the first year of full commercialization.
The September 14 announcement does not specify Mint’s final labeled diabetes indication or age range. Those details should not be inferred from the existing iLet indication, and the company has not stated in this announcement that Mint is cleared for a particular diabetes type or pediatric age group.
3D Intelligence Separates Pump Clearance from the Next Regulatory Step
Beta Bionics has separately submitted 3D Intelligence, its next-generation fully adaptive insulin-dosing algorithm, to the FDA through a 510(k) application.
This distinction is important: Mint has received FDA clearance, but the company has not stated that the complete Mint 3D configuration has already received FDA clearance or that a separate Mint 3D submission has been cleared. Instead, Beta Bionics expects 3D Intelligence to power Mint 3D following regulatory clearance.
The algorithm builds on the company’s experience with iLet, which has been used by more than 40,000 people. It will offer clinicians three selectable algorithm experiences:
- Original: The algorithm currently available with iLet.
- Optimized: An enhanced version incorporating lessons from real-world iLet use.
- Conservative: A more measured approach to correcting elevated glucose levels.
Subject to FDA clearance, Beta Bionics expects to commercialize iLet 3D by the end of 2026 and Mint 3D alongside the full Mint launch in Q1 2027.
Mint Is an Insulin-Only Platform
Mint is being developed as an insulin-delivery system. The September announcement does not describe Mint or Mint 3D as a bihormonal system using both insulin and glucagon.
That distinction matters given Beta Bionics’ broader development history around the concept of a bihormonal artificial pancreas. The Mint platform described in this announcement uses automated insulin dosing and should not be interpreted as incorporating glucagon.
Pharmacy-Based Access
Beta Bionics plans to make Mint available exclusively through the U.S. pharmacy channel at launch. The company expects approximately 40% of insured U.S. lives to have access to Mint through their pharmacy benefit initially, with coverage projected to reach at least 50% within the first year of full commercialization.
The pharmacy strategy is intended to broaden access to patch-based automated insulin delivery and give people with diabetes another option beyond a traditional tubed pump. Beta Bionics also expects pharmacy access for its iLet system to expand in 2027 as the company introduces Mint.
Path Forward
The immediate regulatory milestone is FDA review of the 3D Intelligence 510(k). If cleared, the algorithm would provide the software foundation for both iLet 3D and Mint 3D.
Beta Bionics expects iLet 3D commercialization by the end of 2026, followed by the full Mint launch in Q1 2027. The company is targeting production capacity of at least 1.5 million disposable Mint units in 2027, with the potential to increase output through additional staffing, automation and manufacturing-yield improvements.
Reference
Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm, Beta Bionics, 14 September 2026
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.